Inventor · disambiguated record
Lara C. Czabaniuk
Also filed as: CZABANIUK LARA · CZABANIUK LARA C
7 granted patents·4 pending applications·14 citations·filing 2021–2025
80Inventor score
Top patents by PatentIndex Score
11 records- 0194US11718617B2Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of useAMGEN INC·Filed 2022·Granted Aug 8, 2023·4 cites·30 claims
- 0294US11608344B2Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of useAMGEN INC·Filed 2021·Granted Mar 21, 2023·4 cites·30 claims
- 0393US11912711B2Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of useAMGEN INC·Filed 2022·Granted Feb 27, 2024·3 cites·30 claims
- 0493US11884675B2Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of useAMGEN INC·Filed 2022·Granted Jan 30, 2024·3 cites·30 claims
- 0582US12428425B2Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of useAMGEN INC·Filed 2023·Granted Sep 30, 2025·0 cites·18 claims
- 0681US12319691B2Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of useAMGEN INC·Filed 2023·Granted Jun 3, 2025·0 cites·20 claims
- 0774US2025388574A1Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of useAMGEN INC·Filed 2025·Application pending·0 cites
- 0871US12252489B2Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of useAMGEN INC·Filed 2021·Granted Mar 18, 2025·0 cites·23 claims
- 0962US2025223277A1Complement factor b inhibitors and uses thereofNOVARTIS AG·Filed 2023·Application pending·0 cites
- 1061US2025115572A1Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereofNOVARTIS AG·Filed 2023·Application pending·0 cites
- 1154US2024182456A12-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesityNOVARTIS AG·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Lara C. Czabaniuk files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →